What is Nanolive?
Founded in 2013 and headquartered in Tolochenaz, Switzerland, Nanolive is a biotechnology company dedicated to streamlining live cell imaging and analysis for researchers. The company offers advanced research products designed to enhance the efficiency and depth of cellular studies. Nanolive's technology aims to provide scientists with powerful tools for understanding complex biological processes at the cellular level, contributing to advancements in drug discovery, diagnostics, and fundamental biological research.
How much funding has Nanolive raised?
Nanolive has raised a total of $23.3M across 3 funding rounds:
Private Equity
$2.8M
Unspecified
$514K
Series C
$20M
Private Equity (2014): $2.8M, investors not publicly disclosed
Unspecified (2016): $514K led by Swisscom
Series C (2022): $20M supported by Taiwania Capital and Swisscom Ventures
Key Investors in Nanolive
Taiwania Capital
Taiwania Capital is a venture capital firm focused on early-stage companies, with investment targets in enterprise software, AI, IoT, and next-gen semiconductors, indicating a strategic interest in innovative technology platforms.
Swisscom
Swisscom is a leading Swiss telecommunications provider, suggesting a strategic interest in companies that leverage advanced technology and data, potentially for applications in health tech or life sciences.
Swisscom Ventures
Swisscom Ventures is the venture capital arm of Swisscom, likely focusing on investments that align with telecommunications, digital transformation, and emerging technologies.
What's next for Nanolive?
The recent major strategic investment in Nanolive signals a pivotal moment for the company, likely enabling accelerated product development, market penetration, and the scaling of its operations. This infusion of capital, particularly in the context of its enterprise-level funding history, suggests a strong investor confidence in Nanolive's technology and its potential to disrupt the live cell imaging market. Future strategic initiatives may include expanding its product portfolio, forging new research collaborations, and enhancing its global distribution network to support a growing base of scientific clientele.
See full Nanolive company page
